返回
TScan Therapeutics Inc（TCRX）價格
TCRX 股價走勢圖
TCRX 收益
TScan Therapeutics Inc
$1.13
-0.87%
$-0.01
收盤價：Jan 16, 16:00:00 GMT-5
$1.15
1.77%
$0.02
盤後：Jan 16, 20:00:00 GMT-5
關鍵數據
前收市價
$1.14
開盤價
$1.12
當日範圍
$1.12 - $1.19
52週區間
$0.882 - $2.67
交易量
643.4K
平均成交量
778.3K
每股盈餘 (TTM)
-1.12
股息收益率
--
市值
$65.2M
什麼是 TCRX？
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The firm is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The firm has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.